Chronic kidney disease and role of palliative care

Abstract

Patients with end-stage kidney disease can have complex comorbidities. Nephrologist chooses dialysis over conservative management. But, thinking about quality of life for a patient, collaboration of palliative care with nephrology is the need of hour. Palliative care can provide support with symptom management, advance care planning. Optimal care may be provided to the patients if palliative care is integrated with nephrology. Change in provision of services, simultaneously balancing the need for dialysis and palliative care needs to be taken into account.

Keywords: chronic kidney disease, palliative care, pain in CKD

Introduction

The population of chronic kidney disease (CKD) patients is ever increasing across the globe. Worldwide, over 1.4 million people receive renal replacement therapy and the incidence is growing annually by approximately 8%. The approximate prevalence of CKD in India is 800 per million population (pmp), and the incidence of end-stage renal disease (ESRD) in India is 150–200 pmp. These patients have a shortened life expectancy and a high burden of symptoms. They may be benefitted from early palliative care interventions. Palliative care help in relieving suffering and also, provide best possible measures to improve quality of life for both patient as well as their families irrespective of the stage of disease, in unison with their wishes and preferences.

Why the need of palliative care?

Skills of palliative care should be incorporated into the present medical system to treat CKD and ESRD patients. The principal reasons are as follows: firstly, life expectancy of these patients is significantly shortened. Just above half of dialysis patients (52%) are still alive 3 years after the start of RRT. Secondly, patients with CKD and ESRD suffer a spectrum of symptoms such as pain, fatigue, itching, and difficulty with sleep which need to be taken care. Thirdly, financial burden of dialysis is huge for the patient, family as well as the government. In the UK, there were 54,824 adult patients receiving renal replacement therapy in 2013. The mean annual cost of dialysis per patient is estimated at £27 000. Provision of treatment for ESRD is predicted to consume approximately 2% of the annual National Health Service budget influenced by disproportionate numbers of older, frailter, dependent patients.

In consideration of the high symptom burden and the low survival rate for dialysis patients, the American Society of Nephrology (ASN) and the Renal Physicians Association (RPA) have recommended that dialysis facilities incorporate palliative care into their treatment of patients. Nephrologists have been encouraged to obtain education and skills in palliative care, and dialysis facilities have been urged to develop protocols, policies, and programs to ensure that palliative care is provided to their patients.

Symptom assessment

Identification and management of symptoms in renal patients is very crucial. However, evidence shows that symptoms in renal disease patients are not assessed properly and often go unrecognised.

Tools such as the Modified Edmonton Symptom Assessment System (m-ESAS v. 2) and Palliative Care Outcome Scale (POS-renal) are appropriate for routine clinical screening for pain in renal programs and help redirect care to a more patient centered model.

Symptom management

Pain in CKD

It is well documented in the literature that severe pain is prevalent amongst CKD patients: various publications highlight CKD patients’ experience with pain. Most of these data come from prevalent hemodialysis patients (with 36 studies examining over 5200 patients) and show that over 58% of CKD patients experience pain and 49% of patients rate their pain as moderate or severe. The sources of pain were musculoskeletal (62%) followed by other system (9%), cardiovascular (7%) and others (10%). Haematological/oncological (13%), genitourinary (10%), haematological/oncological (10%), central and peripheral nervous system (9%), cardiovascular (7%) and others (10%). WHO ladder can be used most of the time to manage pain symptoms taking in consideration about the renal function.

Step 1: Paracetamol is safe drug which can be used in renal failure. NSAIDs should be avoided as far as possible because they will further impair renal function.

Step 2: Weak opioids such as Tramadol may be used but the dose should be reduced or the dosing interval should be increased, in addition to monitoring for any adverse effects. Other opioids: codeine, dihydrocodeine and their derivatives should be avoided with the risk of accumulation of the metabolites.

Step 3: Strong opioids include Fentanyl which has no active metabolites and only 10% of the unchanged drug is excreted by the kidneys. There is a possibility of drug accumulation but cautious titration and careful monitoring may prevent toxicity.
is metabolised in the liver to many active metabolites including morphine-3-glucoronide and morphine-6 glucuronide. These metabolites are potent and can cause significant respiratory depression and drowsiness. Both the unchanged drug and the metabolites are excreted by the kidneys and are found to accumulate in renal failure, leading to significant toxicity. These drugs should be avoided in patients with CKD Stage 4 and 5 (eGFR<30 ml/min). Oxycodone is another strong opioid which is metabolised in the liver to active metabolites, noroxycodone and oxymorphone. Both oxycodone and its metabolites are cleared by the kidneys, thus accumulation can occur. If required, the short-acting form should be used at a low dose with an increased dosing interval.

**Management of nausea and vomiting**

Evaluating the likely cause of nausea and vomiting is very important as different anti-emetics work on different receptors. Uraemia may be responsible for accompanied persistent nausea which is best managed by drugs which act at the chemoreceptor trigger zone such as Haloperidol which is the drug of choice for uraemia induced nausea. However, the dose should be reduced due to risk of accumulation and increased cerebral sensitivity. Domperidone/metoclopramide are preferred if delayed gastric emptying is suspected which is commonly seen in diabetic or uraemic neuropathy. Metoclopramide can accumulate in CKD patients with an increased risk of extrapyramidal reactions, therefore dose reduction is required. If nausea and vomiting becomes refractory, Levomepromazine can be used which is a broad spectrum anti-emetic acting at many receptors.

**Management of Uraemia-induced Pruritus**

Pruritus can be triggered due to various factors including uraemia-related abnormalities (calcium, phosphorus and parathyroid hormone metabolism), accumulation of uraemic toxins, systemic inflammation, cutaneous xerosis, the opioid system and serotoninergic system. Management modalities include dialysis, correction of calcium, phosphorus, Gabapentin, phototherapy. However, there is limited evidence with these options.

**Advance care planning**

Advance care planning provides direction to healthcare professionals when a person is not in a position to either make and/or communicate their own healthcare choices. Advance care planning allows for a more patient centred approach rather than the focus being primarily on disease, for instance, centred around dialysis decisions. Advance care planning has been recommended as a central tenet of appropriate Initiation of and Withdrawal from Dialysis. The Renal Physicians Association and the American Society of Nephrology. J Am Soc Nephrol. 2000;11(7):1340–1342.

**Conclusion**

Increasing number of CKD patients is gaining attention of leading nephrologist worldwide to incorporate palliative care in the management of these patients to reduce burden on the families, economy. Clinicians need extensive and specialised expertise in pain symptom management and skills in communication to meet the needs of this population. The ideal approach calls for collaboration between the renal healthcare team and palliative care consultants. Discussion with the patient well in time, with family members and care givers would allow planning for the last days of their lives which could allow a dignified death.

**Acknowledgments**

None.

**Conflicts of interest**

The authors declare there is no conflicts of interest.

**References**


**Citation**


